Walter Van Dyck
YOU?
Author Swipe
View article: Advanced therapy medicinal products are coming of age: A pipeline analysis of the clinical trial landscape
Advanced therapy medicinal products are coming of age: A pipeline analysis of the clinical trial landscape Open
Advanced therapy medicinal products (ATMPs) are a unique class of biological medicines that are based on cells, genes, or tissues. Searching four databases, this analysis identified 2008 trials that investigated ATMPs and characterised the…
View article: Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews
Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews Open
Background New ways of reimbursement for high-cost, one-shot curative therapies such as advanced therapy medicinal products (ATMPs) are a growing area of interest to stakeholders in market access such as industry representatives, legislati…
View article: PD226 Integration Of Patient And Clinician Insights Into The European Union Joint Scientific Consultations And Joint Clinical Assessments
PD226 Integration Of Patient And Clinician Insights Into The European Union Joint Scientific Consultations And Joint Clinical Assessments Open
Introduction To summarize insights generated during the preceding four conventions of the European Access Academy (EAA) regarding the interface of patient organizations and medical societies with the evolving European Union (EU) health tec…
View article: OD28 Towards Implementing New Payment Models For The Reimbursement Of High-Cost, Curative Therapies: Insights From Semi-Structured Interviews
OD28 Towards Implementing New Payment Models For The Reimbursement Of High-Cost, Curative Therapies: Insights From Semi-Structured Interviews Open
Introduction In response to the intricate challenges posed by high-cost, one-shot curative therapies, this study explores what hinders the wide implementation of innovative payment schemes across Europe. Drawing insights from the Belgian s…
View article: Evaluating progress towards implementation of the European HTA Regulation: Insights generated from the European Access Academy's multi-stakeholder survey
Evaluating progress towards implementation of the European HTA Regulation: Insights generated from the European Access Academy's multi-stakeholder survey Open
Objectives: We conducted a multi-stakeholder survey to assess stakeholders' perceptions of the progress made towards the implementation of the European Regulation on Health Technology Assessment (EU HTA R) and to identify and prioritize th…
View article: Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy
Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy Open
View article: An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators Open
Objectives: Stakeholder involvement has long been considered a success factor for a joint European health technology assessment (HTA) process, and its relevance is now anchored in the EU HTA Regulation’s (EU HTAR) legislative wording. Ther…
View article: The role of stakeholder involvement in the evolving EU HTA process: <i>Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire</i>
The role of stakeholder involvement in the evolving EU HTA process: <i>Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire</i> Open
Involvement of all relevant stakeholders will be of utmost importance for the success of the developing EU HTA harmonization process. A multi-step procedure was applied to develop a survey across stakeholders/collaborators within the EU HT…
View article: A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies
A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies Open
Background: Omics technologies, enabling the measurements of genes (genomics), mRNA (transcriptomics), proteins (proteomics) and metabolites (metabolomics), are valuable tools for personalized decision-making. We aimed to identify the exis…
View article: Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries
Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries Open
View article: Patient-Level Effectiveness Prediction Modeling for Glioblastoma Using Classification Trees
Patient-Level Effectiveness Prediction Modeling for Glioblastoma Using Classification Trees Open
OBJECTIVES: Little research has been done in pharmacoepidemiology on the use of machine learning for exploring medicinal treatment effectiveness in oncology. Therefore, the aim of this study was to explore the added value of machine learni…
View article: Nearest Neighbour Propensity Score Matching and Bootstrapping for Estimating Binary Patient Response in Oncology: A Monte Carlo Simulation
Nearest Neighbour Propensity Score Matching and Bootstrapping for Estimating Binary Patient Response in Oncology: A Monte Carlo Simulation Open
View article: The consequences of greater Net Price Transparency for innovative medicines in Europe: Searching for a consensus
The consequences of greater Net Price Transparency for innovative medicines in Europe: Searching for a consensus Open
View article: Real-World Evidence Gathering in Oncology: The Need for a Biomedical Big Data Insight-Providing Federated Network
Real-World Evidence Gathering in Oncology: The Need for a Biomedical Big Data Insight-Providing Federated Network Open
Moving toward new adaptive pathways for the development and access to innovative medicines implies that real-world data (RWD) collected throughout the medicinal product life cycle is becoming increasingly important. Big data analytics on R…
View article: A Typology-Based Decisional Framework To Support Market Access And Reimbursement Decisions For Personalised Medicines
A Typology-Based Decisional Framework To Support Market Access And Reimbursement Decisions For Personalised Medicines Open